semaglutide creatinine in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide in kidney outcomes Obesity

Always check the expiration date (or beyond-use date) of the medication before using it

Discussion The present study used data from two of the SUSTAIN trials to assess the relative cost of control of bringing patients with T2D to a series of clinically relevant targets encompassing glycemic control, hypoglycemia, and weight gain

2 Department of Geriatric Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Peoples Republic of China

The completion rate of the everolimus group is lower due to side effects, and the incidence of grade 3 and 4 adverse events is higher

Eur Heart J - Cardiovasc Pharmacother (2023), pvad080